Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Kelly Slaten"'
Publikováno v:
J Pharm Technol
Background: Risk factors for the development of bacteremia in patients with urosepsis are not well-defined in the current literature. Objective: To assess potential risk factors, including receipt of SGLT2 inhibitor therapy (SGLT2-I), for the develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e6a4c100dec40562653d68b6266352b
https://europepmc.org/articles/PMC9096848/
https://europepmc.org/articles/PMC9096848/
Publikováno v:
Open Forum Infectious Diseases
Background Though sodium-glucose co-transporter 2 (SGLT2) inhibitors have been associated with an increased risk of urinary tract infection, it is unknown whether SGLT2 inhibitors increase the risk of urinary-source bacteremia. Early recognition of b